MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:93M1 • DE000A289V03

22.9 EUR
+0.2 (+0.88%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 93M1. 93M1 was compared to 55 industry peers in the Pharmaceuticals industry. While 93M1 seems to be doing ok healthwise, there are quite some concerns on its profitability. 93M1 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year 93M1 has reported negative net income.
  • In the past year 93M1 had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: 93M1 reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: 93M1 reported negative operating cash flow in multiple years.
93M1.DE Yearly Net Income VS EBIT VS OCF VS FCF93M1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • 93M1 has a worse Return On Assets (-52.66%) than 85.45% of its industry peers.
  • With a Return On Equity value of -56.18%, 93M1 is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -52.66%
ROE -56.18%
ROIC N/A
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
93M1.DE Yearly ROA, ROE, ROIC93M1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

1.3 Margins

  • In the last couple of years the Profit Margin of 93M1 has grown nicely.
  • 93M1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
93M1.DE Yearly Profit, Operating, Gross Margins93M1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • 93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 93M1 has about the same amout of shares outstanding than it did 1 year ago.
  • 93M1 has about the same amout of shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 93M1 has an improved debt to assets ratio.
93M1.DE Yearly Shares Outstanding93M1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
93M1.DE Yearly Total Debt VS Total Assets93M1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 5.49 indicates that 93M1 is not in any danger for bankruptcy at the moment.
  • 93M1 has a better Altman-Z score (5.49) than 72.73% of its industry peers.
  • The Debt to FCF ratio of 93M1 is 5.58, which is a neutral value as it means it would take 93M1, 5.58 years of fcf income to pay off all of its debts.
  • 93M1 has a Debt to FCF ratio (5.58) which is comparable to the rest of the industry.
  • 93M1 has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • 93M1 has a better Debt to Equity ratio (0.02) than 89.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 5.58
Altman-Z 5.49
ROIC/WACCN/A
WACC7.31%
93M1.DE Yearly LT Debt VS Equity VS FCF93M1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • 93M1 has a Current Ratio of 0.40. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.40, 93M1 is doing worse than 92.73% of the companies in the same industry.
  • 93M1 has a Quick Ratio of 0.40. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 93M1 has a worse Quick ratio (0.40) than 87.27% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.4
93M1.DE Yearly Current Assets VS Current Liabilites93M1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for 93M1 have decreased strongly by -196.45% in the last year.
  • The Earnings Per Share has been growing by 23.67% on average over the past years. This is a very strong growth
  • The Revenue has grown by 104.72% in the past year. This is a very strong growth!
  • The Revenue has been decreasing by -6.95% on average over the past years.
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
93M1.DE Yearly Revenue VS Estimates93M1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
93M1.DE Yearly EPS VS Estimates93M1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • 93M1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
93M1.DE Price Earnings VS Forward Price Earnings93M1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • 93M1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 46.69
EV/EBITDA N/A
93M1.DE Per share data93M1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • 93M1 has a Yearly Dividend Yield of 4.98%, which is a nice return.
  • 93M1's Dividend Yield is rather good when compared to the industry average which is at 1.95. 93M1 pays more dividend than 89.09% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.83, 93M1 pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.98%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
93M1.DE Yearly Dividends per share93M1.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
93M1.DE Yearly Income VS Free CF VS Dividend93M1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

More info and screens

Find the best dividend stocksShow peers with best dividend

MPH HEALTH CARE AG KONV

FRA:93M1 (2/6/2026, 7:00:00 PM)

22.9

+0.2 (+0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-20
Earnings (Next)05-26
Inst Owners1.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap98.01M
Revenue(TTM)52.00K
Net Income(TTM)-115.23M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.98%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1884.85
P/FCF 46.69
P/OCF 46.6
P/B 0.48
P/tB 0.48
EV/EBITDA N/A
EPS(TTM)-26.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.49
FCFY2.14%
OCF(TTM)0.49
OCFY2.15%
SpS0.01
BVpS47.93
TBVpS47.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.66%
ROE -56.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 4036.73%
ROA(3y)11.46%
ROA(5y)-0.71%
ROE(3y)12.15%
ROE(5y)-0.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y32.91%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 5.58
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.4
Altman-Z 5.49
F-Score4
WACC7.31%
ROIC/WACCN/A
Cap/Depr(3y)20.66%
Cap/Depr(5y)19.86%
Cap/Sales(3y)15.7%
Cap/Sales(5y)12.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.45%
EPS 3YN/A
EPS 5Y23.67%
EPS Q2Q%-197.62%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)104.72%
Revenue growth 3Y-4.71%
Revenue growth 5Y-6.95%
Sales Q2Q%166.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.36%
FCF growth 3YN/A
FCF growth 5Y-24.11%
OCF growth 1Y40.11%
OCF growth 3YN/A
OCF growth 5Y-24.28%

MPH HEALTH CARE AG KONV / 93M1.DE FAQ

Can you provide the ChartMill fundamental rating for MPH HEALTH CARE AG KONV?

ChartMill assigns a fundamental rating of 2 / 10 to 93M1.DE.


What is the valuation status for 93M1 stock?

ChartMill assigns a valuation rating of 1 / 10 to MPH HEALTH CARE AG KONV (93M1.DE). This can be considered as Overvalued.


Can you provide the profitability details for MPH HEALTH CARE AG KONV?

MPH HEALTH CARE AG KONV (93M1.DE) has a profitability rating of 1 / 10.


How financially healthy is MPH HEALTH CARE AG KONV?

The financial health rating of MPH HEALTH CARE AG KONV (93M1.DE) is 4 / 10.


How sustainable is the dividend of MPH HEALTH CARE AG KONV (93M1.DE) stock?

The dividend rating of MPH HEALTH CARE AG KONV (93M1.DE) is 6 / 10 and the dividend payout ratio is 0%.